Live feed09:00:00·1hPRReleasevia QuantisnowAlpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell CarcinomaByQuantisnow·Wall Street's wire, on your screen.DRTS· Alpha Tau Medical Ltd.Health Care
